COLLEGIUM PHARMACEUTICAL Files Routine 8-K on Jan 1 Event

Ticker: COLL · Form: 8-K · Filed: Jan 3, 2024 · CIK: 1267565

Collegium Pharmaceutical, Inc 8-K Filing Summary
FieldDetail
CompanyCollegium Pharmaceutical, Inc (COLL)
Form Type8-K
Filed DateJan 3, 2024
Risk Levellow
Pages4
Reading Time5 min
Key Dollar Amounts$0.001, $150 million
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: regulation-fd, current-report, disclosure

TL;DR

**COLL filed a routine 8-K, nothing major to see here.**

AI Summary

COLLEGIUM PHARMACEUTICAL, INC. filed an 8-K on January 3, 2024, reporting an event that occurred on January 1, 2024. This filing is a routine current report, indicating no major new financial or operational news, but rather a standard disclosure under Regulation FD and other events. For investors, this means there's no immediate significant news impacting the stock, suggesting business as usual for COLLEGIUM PHARMACEUTICAL, INC. (COLL).

Why It Matters

This filing is a standard disclosure, indicating no immediate material changes or significant events that would drastically alter the company's financial outlook or operations. It's a 'business as usual' update for investors.

Risk Assessment

Risk Level: low — The filing is a standard current report with no specific financial or operational disclosures that would introduce new risks.

Analyst Insight

Smart investors would note this as a routine filing, indicating no immediate catalysts or red flags. It suggests a 'hold' or 'monitor' approach unless other information is available.

Key Players & Entities

  • COLLEGIUM PHARMACEUTICAL, INC. (company) — the registrant filing the 8-K
  • January 1, 2024 (date) — date of the earliest event reported
  • January 3, 2024 (date) — date the 8-K was filed
  • 001-37372 (other) — Commission File Number for COLLEGIUM PHARMACEUTICAL, INC.
  • COLL (other) — Trading Symbol for COLLEGIUM PHARMACEUTICAL, INC. on NASDAQ

FAQ

What is the purpose of this 8-K filing by COLLEGIUM PHARMACEUTICAL, INC.?

This 8-K filing is a 'Current Report' pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934, specifically covering 'Regulation FD Disclosure' and 'Other Events' as of January 1, 2024.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on January 1, 2024.

What is the trading symbol and exchange for COLLEGIUM PHARMACEUTICAL, INC. common stock?

The common stock of COLLEGIUM PHARMACEUTICAL, INC. trades under the symbol 'COLL' on The NASDAQ Global Select Market.

What is the business address of COLLEGIUM PHARMACEUTICAL, INC.?

The business address of COLLEGIUM PHARMACEUTICAL, INC. is 100 Technology Center Drive, Suite 300, Stoughton, MA 02072.

Does this 8-K filing indicate any major financial or operational changes for COLLEGIUM PHARMACEUTICAL, INC.?

Based on the provided text, this 8-K is a routine filing under 'Regulation FD Disclosure' and 'Other Events' without specific details of major financial or operational changes, suggesting it's a standard disclosure rather than a report of a significant new event.

Filing Stats: 1,246 words · 5 min read · ~4 pages · Grade level 13.2 · Accepted 2024-01-03 08:03:11

Key Financial Figures

  • $0.001 — h registered Common stock, par value $0.001 per share COLL The NASDAQ Global Sele
  • $150 million — 4 through June 2025 to repurchase up to $150 million of the Company's shares of common stock

Filing Documents

01

Item 7.01 Regulation FD Disclosure. On January 3, 2024, Collegium Pharmaceutical, Inc. (the "Company") issued a press release announcing full-year revenue, adjusted operating expense and adjusted EBITDA guidance for 2024. The Company also announced that the Board of Directors of the Company authorized a new share repurchase program from January 2024 through June 2025 to repurchase up to $150 million of the Company's shares of common stock, which program is described in more detail under Item 8.01 of this Current Report on Form 8-K. A copy of the press release is attached hereto as Exhibit 99.1 and is being furnished, not filed, under Item 7.01 of this Current Report on Form 8-K. In addition, on January 3, 2024, the Company posted a corporate presentation to its website that representatives of the Company may use from time to time in presentations or discussions with investors, analysts or other parties. A copy of the presentation is attached hereto as Exhibit 99.2 and is being furnished, not filed, under Item 7.01 of this Current Report on Form 8-K. To the extent that the information in this Current Report on Form 8-K, including Exhibits 99.1 and 99.2 furnished herewith, are not descriptions of historical facts regarding the Company, they are forward-looking Litigation Reform Act of 1995. The Company may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Examples of forward-looking statements contained in this Current Report on Form 8-K, including Exhibits 99.1 and 99.2 furnished herewith, include, among others, statements related to the Company's full-year 2024

01

Item 8.01 Other Information. On January 1, 2024, the Board of Directors of the Company authorized a new share repurchase program to repurchase up to $150 million of the Company's shares of common stock through June 30, 2025. The timing and amount of any shares purchased on the open market will be determined based on the Company's evaluation of the market conditions, share price and other factors. The Company plans to utilize existing cash on hand to fund the share repurchase program.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated January 3, 2024. 99.2 Investor Presentation, dated January 3, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: January 3, 2024 Collegium Pharmaceutical, Inc. By: /s/ Colleen Tupper Name: Colleen Tupper Title: Executive Vice President and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.